Vir Biotechnology, Inc. (VIR) Wednesday announced encouraging results from Phase 1 studies of its two drug candidates VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors. The company's shares were more than 38 percent up in pre-market.
VIR-5818 is being evaluated in Phase 1 trial to study its safety and pharmacokinetics alone, and in combination with pembrolizumab, in participants with a variety of HER2-expressing cancers, including breast and colorectal cancer (CRC). Data from the study showed that 50 percent of participants treated with VIR-5818 experienced tumor shrinkage across multiple HER2-positive tumor types.
VIR-5500 is being evaluated in a Phase 1 trial designed to assess its safety, pharmacokinetics, and efficacy in participants with metastatic castration-resistant prostate cancer (mCRPC). Data from the study showed prostate-specific antigen (PSA) reductions in all the participants.
Vir Biotechnology stock had closed at $7.89, down 0.75 percent on Tuesday. It has traded in the range of $6.56 - $13.09 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.